Eversense 365 is said to be the world's first one-year CGM system, offering a new long-term solution for diabetes management.

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

Continuous Glucose Monitoring (CGM) Systems Market The increasing incidence of diabetes and the detection of patient's blood glucose levels are raising the demand for continuous global monitoring ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Their research has been published in Science Advances, titled "Coin-sized, fully integrated, and minimally invasive ...

has cleared the Eversense 365 continuous glucose monitoring (CGM) system for patients aged 18 years and older with type 1 or type 2 diabetes. Eversense ® 365 is a fully-implantable CGM with a 365 ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...

Their research has been published in Science Advances, titled "Coin-sized, fully integrated, and minimally invasive continuous glucose monitoring system based on organic electrochemical transistors." ...